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Aims To develop a document by Brazilian Cardiovascular Imaging Department (DIC) and the European Association of
Cardiovascular Imaging (EACVI) to review and summarize the most recent evidences about the non-invasive
assessment of patients with Chagas disease, with the intent to set up a framework for standardized cardiovascular
imaging to assess cardiovascular morphologic and functional disturbances, as well as to guide the subsequent proc-
ess of clinical decision-making.
...................................................................................................................................................................................................
Methods
and results
Chagas disease remains one of the most prevalent infectious diseases in Latin America, and has become a health
problem in non-endemic countries. Dilated cardiomyopathy is the most severe manifestation of Chagas disease,
which causes substantial disability and early mortality in the socially most productive population leading to a signifi-
cant economical burden. Prompt and correct diagnosis of Chagas disease requires specialized clinical expertise to
recognize the unique features of this disease. The appropriate and efficient use of cardiac imaging is pivotal for diag-
nosing the cardiac involvement in Chagas disease, to stage the disease, assess patients’ prognosis and address man-
agement. Echocardiography is the most common imaging modality used to assess, and follow-up patients with
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Chagas disease. The presence of echocardiographic abnormalities is of utmost importance, since it allows to stage
patients according to disease progression. In early stages of cardiac involvement, echocardiography may demon-
strate segmental left ventricuar wall motion abnormalities, mainly in the basal segments of inferior, inferolateral
walls, and the apex, which cannot be attributed to obstructive coronary artery arteries. The prevalence of segmen-
tal wall motion abnormalities varies according to the stage of the disease, reaching about 50% in patients with left
ventricular dilatation and dysfunction. Speckle tracking echocardiography allows a more precise and quantitative
measurement of the regional myocardial function. Since segmental wall motion abnormalities are frequent in
Chagas disease, speckle tracking echocardiography may have an important clinical application in these patients, par-
ticularly in the indeterminate forms when abnormalities are more subtle. Speckle tracking echocardiography can
also quantify the heterogeneity of systolic contraction, which is associated with the risk of arrhythmic events.
Three-dimensional (3D) echocardiography is superior to conventional two-dimensional (2D) echocardiography for
assessing more accurately the left ventricular apex and thus to detect apical aneurysms and thrombus in patients in
whom ventricular foreshortening is suspected by 2D echocardiography. In addition, 3D echocardiography is more
accurate than 2D Simpson s biplane rule for assessing left ventricular volumes and function in patients with signifi-
cant wall motion abnormalities, including aneurysms with distorted ventricular geometry. Contrast echocardiogra-
phy has the advantage to enhancement of left ventricular endocardial border, allowing for more accurate detection
of ventricular aneurysms and thrombus in Chagas disease.
Diastolic dysfunction is an important hallmark of Chagas disease even in its early phases. In general, left ventricular
diastolic and systolic dysfunction coexist and isolated diastolic dysfunction is uncommon but may be present in
patients with the indeterminate form. Right ventricular dysfunction may be detected early in the disease course,
but in general, the clinical manifestations occur late at advanced stages of Chagas cardiomyopathy. Several echocar-
diographic parameters have been used to assess right ventricular function in Chagas disease, including qualitative
evaluation, myocardial performance index, tissue Doppler imaging, tricuspid annular plane systolic excursion, and
speckle tracking strain.
Cardiac magnetic resonance (CMR) is useful to assess global and regional left ventricular function in patients with
Chagas diseases. Myocardial fibrosis is a striking feature of Chagas cardiomyopathy and late gadolinium enhance-
ment (LGE) is used to detect and quantify the extension of myocardial fibrosis. Myocardial fibrosis might have a
role in risk stratification of patients with Chagas disease. Limited data are available regarding right ventricular func-
tion assessed by CMR in Chagas disease.
Radionuclide ventriculography is used for global biventricular function assessment in patients with suspected or def-
inite cardiac involvement in Chagas disease with suboptimal acoustic window and contraindication to CMR.
Myocardial perfusion scintigraphy may improve risk stratification to define cardiac involvement in Chagas disease,
especially in the patients with devices who cannot be submitted to CMR and in the clinical setting of Chagas
patients whose main complaint is atypical chest pain. Detection of reversible ischemic defects predicts further dete-
rioration of left ventricular systolic function and helps to avoid unnecessary cardiac catheterization and coronary
angiography.
...................................................................................................................................................................................................
Conclusion Cardiac imaging is crucial to detect the cardiac involvement in patients with Chagas disease, stage the disease and
stratify patient risk and address management. Unfortunately, most patients live in regions with limited access to
imaging methods and point-of-care, simplified protocols, could improve the access of these remote populations to
important information that could impact in the clinical management of the disease. Therefore, there are many fields
for further research in cardiac imaging in Chagas disease. How to better provide an earlier diagnosis of cardiac
involvement and improve patients risk stratification remains to be addressed using different images modalities.
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Myocardial sympathetic innervation
Patient risk stratification
Conclusion and future research
Introduction
Chagas disease, caused by the protozoan Trypanosoma cruzi, remains
one of the most prevalent infectious diseases in Latin America and
has become a health problem in non-endemic countries.1,2 Although
public health programs have significantly reduced the prevalence of
Chagas disease in Latin America in recent decades, awareness of the
number of infections in the USA and non-endemic countries in
Europe continues to rise.3
Dilated cardiomyopathy is the most severe manifestation of
Chagas disease and is characterized by heart failure, ventricular an-
eurysms, conduction disturbances, ventricular arrhythmias,
thromboembolism, and sudden death.4,5 The early mortality and sub-
stantial disability caused by this disease, which often manifests in the
socially most productive population (i.e. young adults), result in a sig-
nificant economical burden. Chagas cardiomyopathy (CCM) usually
requires long-term treatment, and can include specialized care, with
pacemaker and cardioverter defibrillator implantation, and heart
transplantation, with further increase of the costs related to the
disease.6
The pathogenesis of chronic CCM has not been completely eluci-
dated. Most investigators believe that the main pathogenetic mechan-
isms of CCM are dependent on the parasite driven inflammatory
reaction and the adverse host immune response.7 Autoimmunity
mechanisms, probably related to the parasite persistence, involving
polyclonal activation, molecular self-mimicry by parasite antigens or
cryptic epitopes may also be implicated in the development of
CCM.7 Two other mechanisms are thought to contribute to the
pathogenesis of CCM: neurogenic disturbances and microvascular
derangements.7,8
Prompt and correct diagnosis of Chagas disease requires special-
ized clinical expertise to recognize the unique features of this disease.
The appropriate and efficient use of cardiac imaging is pivotal for diag-
nosing the cardiac involvement in Chagas disease, to stage the dis-
ease, assess patients’ prognosis and address management.
Accordingly, Brazilian Cardiovascular Imaging Department (DIC)
and the European Association of Cardiovascular Imaging (EACVI) de-
veloped this document to review and summarize the most recent
evidences about the non-invasive assessment of patients with Chagas
disease, with the intent to set up a framework for standardized and
efficient use of cardiovascular imaging to assess cardiovascular mor-
phologic and functional disturbances, as well as to guide the subse-
quent process of clinical decision-making.9
Epidemiology, diagnosis, clinical
manifestations, and prognosis
Chagas disease is endemic in Latin American countries, where nearly
6 million people are currently estimated to be infected with T. cruzi.10
Argentina, Brazil, Mexico, and Bolivia were the countries with higher
estimated number of infected people (1.5, 1.2, 0.9, and 0.6 million,
respectively).11 These numbers, much lower than previous estimates,
seem to reflect the good result of coordinated multi-country initia-
tives, supported by Pan American Health Organization and World
Health Organization, for vectorial and blood-borne transmission
control.
Due to migration flows from Latin American endemic countries to
the USA, Europe, and other developed countries, Chagas disease pa-
tients can now be found in alarming numbers outside the endemic
countries. In Europe, the prevalence of Chagas disease in Latin
American immigrants is high (4.2%), particularly in migrants from
Bolivia and Paraguay,12 although a reliable estimate on how many in-
fected persons are living in Europe is still lacking.13
Chagas disease is transmitted to humans by infected triatomine
bugs, through blood transfusion, organ transplantation, congenital
transmission, oral ingestion of contaminated materials, or accidental
contamination during laboratory work.14 The natural history of
Chagas disease is characterized by two well-established phases
(Figure 1). The acute phase, with high-grade parasitaemia and prolifer-
ation of amastigote forms in various organs, lasts from 4 to 8weeks,
is usually oligosymptomatic and is diagnosed in only 1–2% of the
cases. The mortality rate is around 1% in the acute period, usually
due to severe myocarditis or meningoencephalitis tissues.15,16 Given
the high rates of pericardial effusion, echocardiography is indicated in
patients present with acute Chagas disease.
The chronic phase is characterized by two distinct clinical forms.
The indeterminate form, which is usually installed 4–10weeks after
infection, is defined by seropositivity, and lack of radiologic, electro-
cardiographic and clinical manifestations of cardiac and digestive dis-
ease.17 However, cardiovascular abnormalities can be detected using
specific non-invasive tests, such as echocardiogram,18,19 cardiac mag-
netic resonance (CMR) and autonomic tests.20–22 Although most pa-
tients remain with the indeterminate form throughout life, others
evolve to a determined form of the disease 10–30 years after the
acute infection, affecting specific organs, such as the heart, oesopha-
gus and colon, which characterize distinct chronic cardiac, digestive,
or mixed forms.23 The progression from indeterminate to cardiac
form ocurrs at an average rate of around 2% per year.24,25
The cardiac form is usually initially defined by the presence of typ-
ical electrocardiographic abnormalities that encompass a wide spec-
trum of presentations, from minor electrocardiographic alterations
with normal left ventricular (LV) systolic function, to various forms of
arrhythmia, and to dilated cardiomyopathy with heart failure.17,26,27
The CCM, which constitutes themost serious complication of the dis-
ease, occurs in 20–40% of those individuals tested serologically posi-
tive.28 Up to 15–20% of patients with indeterminate form develop
digestive alterations in some endemic areas, but the prevalence seems
to vary among countries possibly due to different inoculated strain.14
The chronic cardiac form manifests itself by one of the three main
syndromes, which can occur in association: heart failure, cardiac ar-
rhythmias, and pulmonary or systemic thromboembolism. The initial
manifestations of CCM are generally mild and most patients have
asymptomatic electrocardiogram (ECG) alterations, such as right
bundle branch block and bradycardia,26 and minor echocardiographic
abnormalities, e.g. regional wall motion abnormalities29 (Table 1).
Ventricular arrhythmias are important manifestations of CCM and
non-sustained ventricular tachycardia is an established marker of
higher risk of death.30,31
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Patients with more advanced disease frequently have heart failure,
which is associated with an ominous prognosis and seems to be car-
rying higher mortality risk than ischaemic or idiopathic dilated
cardiomyopathies.32,33
Stroke is also a cause of death in association with advanced heart
disease,34 but could also be the first sign of CCM in asymptomatic pa-
tients and those with mild LV systolic dysfunction.35 LV aneurysm,
mural thrombus, and atrial fibrillation are risk factors for stroke
related to CCM.36
The aetiologic diagnosis of chronic Chagas disease is based on
serological assays because the direct detection of parasites is difficult
due to very low levels or even absence of parasitaemia.37 There are
several techniques used for detection of antibodies against the T. cruzi
including indirect immunofluorescence, enzyme immunoassays
(ELISAs), haemaglutination and rapid test provided by different manu-
facturers.38 Their sensitivity may vary significantly and Chagas disease
should be screened by 2 different parallel assays.39 However, as the
ELISA tests were more broadly used in the blood bank setting, the
sensitivity of the assays improved and the current predominant con-
sensus is that a single highly sensitive assay can be used for the initial T.
cruzi screening, so that, if negative, it would rule out this aetiology.38
Regarding the prognosis of the disease, several risk markers
have been recognized, and a systematic review identified that im-
paired LV function, New York Heart Association class III/IV, car-
diomegaly, and non-sustained ventricular tachycardia are the most
important predictors of poor prognosis in patients with chronic
CCM.40 Using a validated prognostic scoring system, based on
clinical, radiological, echocardiographic and Holter monitoring/
stress testing, Chagas disease patients can be stratified into three
risk groups: low, intermediate, and high.30 For those at low risk,
90% will still be alive after 10 years, in comparison with only 16%
of those at high risk. Prognostic factors have been used to build a
risk score for death that is helpful for clinical decision making30
(Table 2).
Key points
• 20–40% of patients with Chagas disease will evolve to chronic
Chagas cardiomyopathy, which can be asymptomatic or manifest
by heart failure, cardiac arrhythmias, and/or thromboembolism
• Brady or tachyarrhythmias or stroke may be the first manifestation
of Chagas cardiomyopathy
.................................................................................................
Table 1 Stages in the development of heart failure
due to Chagas disease
Stages Findings
A Patients present no symptoms of heart failure, and no
structural heart disease (normal ECG and chest X-ray)
B1 Asymptomatic patients with ECG changes (arrhythmias or
conduction disorders); mild echocardiographic contract-
ile abnormalities with normal global ventricular function
can also be present
B2 Patients with impaired left ventricular ejection fraction
who have never had any signs or symptoms of heart
failure
C Patients with left ventricular dysfunction and prior or cur-
rent symptoms of heart failure
D Patients with symptoms of heart failure at rest, refractory
to maximized medical therapy (NYHA IV) that require
specialized and intensive interventions
ECG, electrocardiogram; NYHA, New York Heart Association.
Figure 1 Natural history of Chagas disease. Adapted from Lancet 2010;375:1388–1402. A direct progression from the acute phase to a clinical
form of Chagas disease has been recorded in less than 5–10% of cases.
4 M.C.P. Nunes et al.
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.• Chronic form of Chagas cardiomyopathy evolving to heart failure
carries higher mortality
• Impaired LV systolic function, New York Heart Association class
III/IV, cardiomegaly, and non-sustained ventricular tachycardia are
important predictors of poor prognosis in patients with chronic
Chagas disease
LV systolic function
Echocardiography
Echocardiography is the most commonly used imaging modality for
assessment and follow-up of patients with Chagas disease.41
Echocardiography allows to stage patients (A, B, C, and D) according
to international recommendations adapted to the Chagas disease
(Table 1).17,41 In early stages of cardiac involvement, echocardiog-
raphy may demonstrate segmental LV wall motion abnormalities and
diastolic dysfunction.4,42,43 The most commonly involved LV regions
are the basal inferior and inferolateral walls (Figure 2; Supplementary
Videos 1 and 2), and the apex, which cannot be attributed to ob-
structive coronary artery.44 Wall motion abnormalities can be de-
tected in more than one wall in the same patient. The extent of
regional wall motion abnormality varies from hypokinesis to akinesis
and aneurysm. The presence of segmental abnormalities identifies in-
dividuals at risk of further LV function global deterioration.45
Wall motion abnormalities can be found in around 10% of patients
in the early stages of cardiac involvement and they can be associated
with ventricular arrhythmias.46 As the disease progresses to LV dila-
tation and dysfunction, the prevalence of segmental wall motion
abnormalities increases to about 50% of patients.47,48
Detection of regional wall motion abnormalities by visual
assessment is subjective and highly dependent on the skills of the in-
terpreter. Moreover, subtle changes in segmental contractility may
be missed by visual assessment. Strain measurement using speckle
tracking echocardiography is a new method that allows a more
precise and quantitative measurement of the regional myocardial
function, overcoming the subjective evaluation by conventional
echocardiography (Figures 3 and 4).49,50 Since segmental wall motion
abnormalities are frequent in Chagas disease, speckle tracking
echocardiography may have an important clinical application in these
patients, particularly in the indeterminate forms when abnormalities
are more subtle. A study including 125 patients with Chagas disease
found that global longitudinal, circumferential, and radial LV strain
were reduced in the patients who had cardiac fibrosis on CMR des-
pite normal global and segmental LV systolic function by echocardi-
ography.51 Specifically, the patients with fibrosis had lower radial LV
strain in the basal inferoseptal wall than patients without cardiac
fibrosis (27± 17% vs. 60± 15%).
Speckle tracking echocardiography can also quantify the het-
erogeneity of systolic contraction, which is associated with the
risk of arrhythmic events. A recent study showed that mechanical
dispersion was associated with malignant ventricular arrhythmias
in patients with CCM independent of LV ejection fraction
(Figure 5).52
LV apical aneurysms are a typical finding in patients with CCM and
can be helpful in making the aetiologic diagnosis in dilated cardiomy-
opathy (Figure 6; Supplementary Videos 3 and 4).4,44,47 This abnor-
mality may be missed if only conventional apical views are acquired.
.................................................................................................
Table 2 Score for predicting all-cause mortality in
Chagas disease (Rassi’s score)30
Predictors Points
New York Heart Association class III or IV 5
Cardiomegaly (chest X-ray) 5
Segmental or global wall motion abnormality (echo) 3
Non-sustained ventricular tachycardia (24 h Holter) 3
Low QRS voltage (ECG) 2
Male sex 2
Risk category 5-years mortality 10-years mortality Total points
Low 2% 10% 0–6
Intermediate 18% 44% 7–11
High 63% 84% 12–20
ECG, electrocardiogram.
Figure 2 (A) Apical two-chamber view 2D echocardiographic image showing akinesis of the basal segment of the inferior wall. (B) Apical long-axis
view showing akinesis of the basal segment of the inferolateral wall.
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Figure 4 Computation of peak LV global longitudinal strain by using the speckle tracking technique on three conventional apical views: four-cham-
ber (left, upper panel), two-chamber (right, upper panel), and apical long axis (left, lower panel). LV segmental values of longitudinal strain are displayed
both as numbers and as parametric colorization on a bull’s eye display (right, lower panel). There is an apical aneurism that is seen in each view.
Figure 3 Left ventricular longitudinal strain at apical two-chamber view (left, upper panel) in an asymptomatic patient with Chagas disease and nor-
mal global left ventricular ejection fraction. The regional strain values are displayed both as regional strain (left, lower panel) and time curves (right,
upper panel) as well as in an M-mode parametric colourization (right, lower panel). AVC, aortic valve closure.
6 M.C.P. Nunes et al.
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In order to identify aneurysms, a careful examination requires not
only standard views but also angulated apical views. Frequently, a
modified four- and two-chambers views aiming posteriorly may be
necessary to detect apical aneurysms and thrombus. The size of the
aneurysm may range from small (like a ‘hollow punch’) to large with
extensive wall thinning, similar to ischaemic aneurysms.44,47
Aneurysms are not limited to the apex or to the inferolateral wall,44
they can also be found in interventricular septum and anterolateral
walls, being more prevalent in patients with global LV systolic dys-
function.44,47 Previous studies using 2D echocardiography reported
that the LV aneurysm prevalence was 8.5% (ranging from 1.6 to
8.6%) in asymptomatic patients but increased to 55% (ranging from
47 to 64%) in patients with moderate or severe LV global systolic
dysfunction.44,47,48 Right ventricular (RV) aneurysms are uncommon,
but some patients have apical aneurysms affecting both ventricles
(Figure 6; Supplementary Video 4). Intraventricular mural thrombi can
be associated with aneurysms and are important risk factors for
the occurrence of systemic embolisms including stroke35,36,53,54
(Figure 7; Supplementary movies 5 and 6).
Contrast echocardiography has the advantage to enhancement
of LV endocardial border, allowing for more accurate detection of
ventricular aneurysms and thrombus in Chagas disease.44 With
the apical four-chamber view, using contrast echo, it should be
usually possible to clearly visualize the RV and LV cavities.
Figure 6 Apical four-chamber views showing left ventricular ap-
ical aneurysm (thin arrow, on the left), and right ventricular aneur-
ysm (broad arrows, on the right) with a relatively normal left
ventricle.
Figure 5 2D LV longitudinal strain in Chagas disease. Note the progressive decrease in LV longitudinal strain from patient in indeterminate form
(A) to the patients with cardiac form of Chagas disease (B and C). Each figure depicts the LV longitudinal strain curves for each of 6 segments analysed
at the four-chamber view.
Figure 7 Echocardiographic images showing different locations
of thrombus inside of the left ventricle.
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In Chagas disease, 3D echocardiography is superior to 2D echo
for assessing more accurately the LV apex and thus to detect apical
aneurysms/thrombus in patients in whom LV foreshortening is sus-
pected by 2D echo (Figure 8). In addition, 3D echo is more accurate
than 2D Simpson’s biplane rule for assessing LV volumes and EF in pa-
tients with significant wall motion abnormalities, including aneurysms
with distorted LV geometry.
Although segmental wall motion abnormalities are among the most
characteristic findings of cardiac involvement in Chagas disease, their
pathogenesis has not been defined. Since the epicardial coronary
arteries are angiographycally normal it has been hypothesized that
microvascular involvement leads to ischaemia and necrosis in distal
watershed areas of the coronary territories.55,56 This could explain
the prevalence of fibrotic lesions55 and perfusion defects in inferior,
inferolateral and apical segments.56 Accordingly, the regions of late
gadolinium enhancement (LGE) (signifying myocardial fibrosis/scar-
ring) in the post-contrast CMR images are predominantly localized in
the apex, inferior and inferolateral walls.57
More advanced disease is characterized by global LV dilatation and
diffuse hypokinesia. LV systolic dysfunction is the strongest predictor
of death in CCM.40,58
Key points
• Echocardiography is the most common imaging modality used to
assess, stage, and follow-up of patients with Chagas disease
• In early stages of cardiac involvement, echocardiography may dem-
onstrate segmental LV wall motion abnormalities
• Segmental wall motion abnormalities are more frequent in inferior
and inferior-lateral walls and at the apex and may range from
hypokinesis to aneurysms
• Apical aneurysms are the landmark lesions in Chagas disease, but
they can be missed in conventional 2D apical views due to apical
foreshortening, dropout or near-field artefacts
• The use of contrast is highly recommended whenever the image
quality is suboptimal (>2 LV segments not visible, as recom-
mended by guidelines) and when apical involvement is either sus-
pected or unclear
• Speckle tracking longitudinal strain and 3D echocardiography ap-
pear to be accurate and reproducible methods to assess LV sys-
tolic function in Chagas disease and should be used when available
and feasible
Cardiac magnetic resonance
Due to its unique ability to differentiate tissue characteristics, CMR
allows non-invasive tissue characterization in CCM. CMR can dem-
onstrate all the typical features of the cardiac involvement in Chagas
disease such as the presence of myocardial oedema, and altered myo-
cardial perfusion in the early stages, as well as global and segmental
wall motion abnormalities, aneurysm formation, intracardiac thrombi
and myocardial fibrosis areas detected by the LGE sequence in the
most advanced stages (Figure 9).
A study59 showed that 20% of patients in the indeterminate form of
Chagas disease have evidence of myocardial fibrosis, without any asso-
ciated wall motion abnormality. In CCM, CMR highlights the structural
derangement associated with intense collagen formation. Moreover,
the apical aneurysms can be easily demonstrated by CMR (Figure 10).
In advanced stages, the cine sequences show decreased global con-
tractility and ejection fraction with diffuse parietal thinning.59
Regions of LGE with a heterogeneous pattern at delayed enhance-
ment CMR images have been reported in 68.6% of patients at differ-
ent stages of Chagas disease.57 The extension of myocardial fibrosis
correlated with the severity of the LV systolic dysfunction, which was
also present in all patients with previously documented episodes of
ventricular tachycardia.57
Another study60 reported that, in patients with Chagas disease the
prevalence of LGE was 24% in the overall study population.
Particularly, in patients with only electrocardiographic abnormalities,
LGE was found in 16% of patients and 3% had segmental dyskinesia
(aneurysm) not detected with echocardiography. Conversely 52% of
the patients with CCM had LGE indicating myocardial fibrosis and/or
necrosis. The LGE appearance was heterogeneous: subendocardial
in 26.8%, midwall in 14.0%, subepicardial in 22.6%, and transmural
in 36.0% of the patients. The presence of LGE was significantly associ-
ated with lower LV ejection fraction and was more commonly
located at the apex and inferolateral walls. In this study, a correlation
between LGE and arrhythmic events was identified. Thus, early de-
tection of oedema and/or myocardial fibrosis by CMRmay potentially
identify patients at risk of disease progression.57
In 41 patients with Chagas disease and cardiac involvement,
myocardial fibrosis was detected in all the 26 patients (63%) who had
ventricular tachycardia.61 The presence of two or more LV segments
containing transmural LGE constituted a predictor of the occurrence
of arrhythmia after adjustment for LV ejection fraction, age, gender
and the area of LGE. Patients without previous ventricular tachycar-
dia, or transmural LGE, and those with less than 6% of fibrosis in the
myocardium showed no new arrhythmic events. Furthermore, three
patients died of sudden death, and all of them had at least one seg-
ment with transmural LGE at CMR and no previous history of ven-
tricular tachycardia.61
Figure 8 3D echocardiography of a patient with chronic Chagas
disease showing apical aneurysm with preserved contractility at
basal segments of the left ventricle. Semiautomatic endocardial bor-
der detection is shown by yellow line and the lower right panel
shows regional-ventricular analysis.
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Key points
• CMR should be indicated in selected patients with severe ventricu-
lar arrhythmias to quantify the extension of myocardial fibrosis
and risk of sudden death with potential impact on indication of
implantable cardioverter-defibrillator.
• CMR should be indicated for LV ejection fraction evaluation when
contrast echocardiography/3D echo is not available or
unsatisfactory
• It remains to be clarified whether in the patients with the indeter-
minate form of the disease, evidence of oedema or fibrosis at
CMR can predict future progression to the cardiomyopathy
Radionuclide ventriculography
Planar ECG-gated radionuclide ventriculography (RNV) is an alterna-
tive method for LV systolic function assessment in patients with sus-
pected or definite cardiac involvement in Chagas disease when CMR is
not feasible or available.62 RNV was used to assess global LV function,
and also allows the adequate evaluation of regional ventricular wall
motion, particularly the characterization of the apical aneurysm.62
Moreover, data about LV function are robust and reproducible.
Key points
• RNV is used for LV systolic function assessment in those patients
in whom CMR is not feasible or available.
• RNV should be indicated for LV ejection fraction measurement
and regional wall motion evaluation when contrast echocardiog-
raphy/3D echo is not available or unsatisfactory
LV diastolic function
Chagas disease may also lead to impairment of diastolic function,
which can occur early in the disease.18,43,63 Usually, the first abnor-
mality is impaired LV relaxation with prolonged E-wave deceleration
time. Further progression of the disease leads to decreased LV com-
pliance and results in increased filling pressures.4,28,51,63
In some studies, prevalence of diastolic abnormality ranges from
10% of patients with indeterminate form to almost 100% in patients
with CCM and heart failure.43,48,63 Other studies enrolling patients
with the indeterminate form did not show any impairment of diastolic
function.64,65 Differences regarding patient population sampling, con-
trols selection and echocardiographic diastolic parameters used to
define diastolic dysfunction, may explain discrepant results.
More recently, key variables to assess LV diastolic function includ-
ing tissue Doppler imaging have been used that allow comparison
among the studies. In particular, e’ velocity at tissue Doppler echocar-
diography appeared to be the best parameter to identify the progres-
sive worsening of the LV diastolic dysfunction.43,63
Echocardiographic parameters of diastolic function in CCM are
also correlated with brain natriuretic peptide levels.66–68 A previous
study including 59 patients with dilated CCM showed a strong
Figure 9 Cardiac magnetic resonance short axis images showing lateral and septal myocardial fibrosis with a delayed enhancement sequence.
Figure 10 Cardiac magnetic resonance showing the typical apical
aneurysm in a patient with Chagas disease.
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correlation between LA volume and BNP levels.66 In another study,
BNP levels correlated with diastolic function patterns regardless of
systolic function. The E/e’ ratio was the only parameter of diastolic
function that was independently associated with BNP levels.67
Key points
• Isolated LV diastolic dysfunction is uncommon but may appear
early in the natural history of chronic Chagas cardiomyopathy, and
has been described in patients with the indeterminate form of the
disease
• Diastolic and systolic dysfunction coexist in most patients with
more advanced stages of the disease
• Left atrial volume and E/e’ ratio correlate with brain natriuretic
peptide levels in Chagas cardiomyopathy
RV function
RV systolic dysfunction may be an early finding in the natural history
of Chagas disease and has been detected in patients with the indeter-
minate and digestive forms.19,69,70 Several indexes and methods have
been used to describe RV dysfunction in patients with Chagas disease
showing somewhat discrepant results. These mixed data may be
attributed to the different methods used to assess RV function as
well as to the composition of the various groups of patients included
in each study.
Isolated right-sided heart failure is not frequent and usually RV dys-
function is associated with LV dysfunction at advanced stages of
CCM.4,28,71 However, direct damage to the RV myocardium due to
Chagas disease itself can also contribute to RV dysfunction.72–74 It is
important to emphasize that RV dysfunction may occur without
symptoms or signs of heart failure, but may be aggravated by the bur-
den generated by chronic pulmonary hypertension secondary to LV
systolic dysfunction. In such circumstances RV dysfunction carries an
adverse prognostic meaning.70 Also, the concomitance of RV dys-
function explains why systemic congestion can predominate over
pulmonary congestion in some patients with heart failure due to
CCM.71
Echocardiography for RV function
assessment
RV dysfunction has been reported in all stages of Chagas dis-
ease,19,69,70,72,73 most commonly associated with LV dysfunction.
Several echocardiographic parameters have been used to assess RV
function in Chagas disease, including qualitative evaluation, myocar-
dial performance index, tissue Doppler imaging, tricuspid annular
plane systolic excursion, and speckle tracking strain.63,64,73
Cardiac magnetic resonance
Previous studies in Chagas disease using CMR have focused on the
LV and there are limited data on RV function. A study including 158
patients with Chagas disease showed that RV systolic dysfunction as-
sessed by CMR was more commonly associated with reduced LV
ejection fraction. Isolated RV dysfunction was not frequent, which
was identified in only 4.4% of the patients.75
Radionuclide ventriculography
Previous studies using RNV to assess quantitatively RV function have
documented early and predominant RV dysfunction in patients with
the indeterminate and gastrointestinal forms of Chagas disease.69,70
This particular feature explains why heart failure syndrome in some
CCM patients may present more prominent systemic than pulmon-
ary congestion.74
Key points
• Early and predominant RV dysfunction may be present in some
patients with Chagas disease, and in some those with the isolated
gastrointestinal or the indeterminate forms of Chagas disease
• It remains to be clarified whether RV dysfunction is predominantly
secondary to chronic pulmonary hypertension induced by LV sys-
tolic dysfunction or reflects primarily a direct myocardial damage
• Although RNV is a well validated and reproducible technique to
evaluate the RV, limited data are available in Chagas disease.
Disturbances of the coronary
circulation
Although the epicardial coronary arteries are angiographically normal
in the vast majority of patients with Chagas disease studied because
of atypical angina, there is limited evidence of abnormal regulation at
the macrovascular level.7 Moreover, much more evidence has been
gatthered from several studies pointing to functional and structural
microvascular derangements likely to contribute to ventricular dys-
function in Chagas disease.56
On the basis of sporadic cases of myocardial infarction occurring
in Chagas patients with non-obstructed epicedial coronary arteries,
coronary vasospasm has been postulated to cause such events.76
However, controlled studies aiming at detection of abnormal macro-
vascular coronary regulation in Chagas patients produced mixed re-
sults, using various endothelium dependent and endothelium
independent stimuli such as hyperventilation, nitrates, acetylcholine
and adenosine.56,77,78
Wall motion abnormalities have been detected during standard
dobutamine stress echocardiography in patients with Chagas disease,
despite absence of haemodynamically significant obstructions of epi-
cardial coronary arteries79 Abnormal flow regulation at the micro-
vascular level has been demonstrated by several investigators.80,81–83
using myocardial perfusion scintigraphy (Figure 11). Myocardial perfu-
sion defects occur at early stages of Chagas disease at a microvascular
level and precede the appearance of regional systolic wall motion
abnormalities.56,83–86 These data further support the hypothesis that
coronary microvascular disturbances may cause ischaemic myocar-
dial damage in CCM.
Key points
• Wall motion abnormalities may be induced during stress echocar-
diography in Chagas disease patients despite angiographically nor-
mal coronary arteries
• Myocardial perfusion defects occur at early stages of cardiac in-
volvement in Chagas disease, before the appearance of regional
wall motion abnormalities
• Perfusion defect locations are correlated with subsequent devel-
opment of regional myocardial fibrosis
10 M.C.P. Nunes et al.
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• Detection of reversible ischaemic defects predicts further deteri-
oration of LV systolic function
Myocardial sympathetic
innervation
Necropsy studies documented severe cardiac autonomic denerv-
ation in CCM, more severe than in other cardiomyopathies.87,88
Moreover, functional abnormalities of the reflex autonomic control
of the heart rate have been demonstrated using several methods of
investigation.7 More recently, studies using myocardial scintigraphy
with iodine-123-metaiodobenzylguanidine (123I-MIBG) have shown
that defects of 123I-MIBG uptake can be documented in the majority
(68%) of the patients with Chagas disease.56,85,89 Of note, 123I-MIBG
defects were detected in 33% of the patients without any other evi-
dence of cardiac involvement. Patients with more severe LV dysfunc-
tion presented a higher prevalence of 123I-MIBG defects (92%). The
areas of myocardial sympathetic denervation were topographically
correlated with the regions also exhibiting fixed and reversible myo-
cardial perfusion defects and abnormal segmental LV wall motion.
These areas were predominantly the inferior, postero-lateral and ap-
ical LV walls (Figure 12). These findings suggested that myocardial
sympathetic denervation is an early phenomenon in the pathophysi-
ology of Chagas disease, preceding the development of regional LV
wall motion abnormalities. This concept was corroborated by an
independent study showing abnormal 123I-MIBG uptake even in
patients with Chagas disease and no apparent cardiac involvement.90
One investigation in 26 patients with Chagas disease and normal
or mildly reduced LV ejection fraction showed that patients with sus-
tained ventricular tachycardia had higher 123I-MIBG summed score
and a higher number of mismatch defects (sympathetic denervation
with preserved perfusion) per patient than patients with no arrhyth-
mias.89 Both groups had similar 99mTC-Sestamibi-SPECT summed
score. The presence of>_ 3 mismatch defects was strongly associated
with the occurrence of sustained ventricular tachycardia (93%
sensitivity, 82% specificity). These findings suggest a possibly rele-
vant role of myocardial sympathetic denervation as a triggering
mechanism of malignant ventricular arrhythmias, and that 123I-
MIBG imaging may be useful to stratify the risk of sudden cardiac
death in Chagas disease.89
Key points
• Myocardial sympathetic denervation is an early occurrence in pa-
tients with Chagas disease and can be detected using myocardial
scintigraphy with iodine-123-metaiodobenzylguanidine
• The extension of myocardial sympathetic denervation correlates
with the severity of LV dysfunction
• Extent of cardiac sympathetic denervation may be a marker of
ventricular arrhythmias with potential for risk stratification of sud-
den death in Chagas disease
Figure 11 Myocardial perfusion scintigraphy. Images of myocardial perfusion scintigraphy at rest and during exercise showingmostly reversible re-
gional myocardial perfusion defects in the apical and inferolateral left ventricular segments.
Figure 12 Myocardial sympathetic innervation. Images of resting
myocardial perfusion scintigraphy (99mTcMIBI) and of sympathetic
innervation (123IMIBG) with tomographic sections of two orthog-
onal planes (short and long axis). Severely impaired 123IMIBG up-
take with normal myocardial perfusion involves predominantely the
inferior, posterior-lateral, and apical left ventricular walls (A)
Control; (B) Patient with Chagas disease).
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Imaging modalities for risk
stratification
Echocardiography can provide key data to guide therapy and progno-
sis. Several echocardiographic variables have been described as pre-
dictors of mortality in Chagas disease.91 Early studies have identified
LV dysfunction and specially low-ejection fraction obtained by echo-
cardiography as the strongest predictor of death.30,40,44,58,92
Subsequently, echocardiographic parameters to assess LV filling pres-
sure have been reported to have additive value for risk stratification
of patients with impaired LV systolic function.92
....................................................................................................................................................................................................................
Table 3 Echocardiographic predictors of outcomes in Chagas disease
Author/year Number
of patients
Characteristics
of Chagas
disease
patients
Follow-up
duration
Outcomes Echocardiography
predictive
variablesa
Other prognostic
factors
Viotti et al.
(2005)94
856 Indeterminate
form and heart
disease, without
heart failure
8 y Progression of the disease
or cardiovascular death
LV end-systolic
diameter
Age, ICD, SVT, and benz-
nidazole treatment
Rassi Jr et al.
(2006)30
424 Heart disease 7.9 ± 3.2 y All cause-mortality LV systolic dysfunction
subjectively estimated
NYHA class, cardio
megaly, NSVT, QRS
voltage and male
Benchimol
Barbosa
(2007)95
50 Indeterminate
form and heart
disease
84.2 ± 39 m Cardiac death or docu-
mented ventricular
tachycardia
Apical aneurysm and
LVEF
Isolated PVC count
Theodoropoulos
et al. (2008)96
127 Heart failure with
LV systolic
dysfunction
25± 19 m All cause-mortality LVEF NYHA class IV, no BB
therapy, digoxine use,
low serum sodium
levels
Issa et al.
(2010)97,b
68 Irreversible
chronic heart
failure
1326± 39 d Death or heart transplant LV end-diastolic
diameter
BB therapy
Sarabanda and
Marin-Neto
(2011)98
56 Heart disease with
either sustained
VT or NSVT
38± 16 m All cause-mortality and
sudden death
LVEF< 40% None
Ribeiro et al.
(2011)99
113 Indeterminate
form and heart
disease
106± 28 m Cardiovascular death LVEF T-wave variability, NSVT
and QSR>130ms
Bestetti et al.
(2011)100
231 Chronic heart
failure
19 m Death or heart transplant LV end-systolic
diameter
No BB therapy and ino-
tropic support
Duarte et al.
(2011)101
56 Dilated
cardiomyopathy
21± 14 m Death or hospitalizaton Rassi’s score LV dyssynchrony was
not associated with
events
Nunes et al.
(2012)71
232 Dilated
cardiomyopathy
3.4 y Death or heart transplant LVEF, RVMPI, LA vol-
ume, and E/e’ ratio
NYHA class
Nascimento et al.
(2013)63
251 Indeterminate
form and heart
disease
842± 245 d All-cause mortality,
stroke, heart transplant,
worsening HF or
arrhythmias
E’ velocity and peak
negative global LA
strain
None
Rassi et al.
(2014)102
60 Heart failure with
severe LV
systolic
dysfunction
24 m Cardiovascular death Indexed LA volume None
AF, atrial fibrillation; BB, beta-blocker; CI, confidence interval; ICD, intraventricular conduction disorders; d, days; LA, left atrium; LVEDD, left ventricular end-diastolic diameter;
LVSD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; m, months; NYHA, New York Heart Association; QTd, QT dispersion; RVMPI, Right ven-
tricular myocardial performance index; SVT, sustained ventricular tachycardia; NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia; Y, years.
aMultivariate analysis.
bClinical trial; 456 patients with heart failure were enrolled, and Chagas cardiomyopathy was present in 68 patients.
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The ratio of early transmitral velocity to tissue Doppler mitral an-
nular early diastolic velocity (E/e’ ratio), an accepted non-invasive
method to estimate LV filling pressures, is also an independent pre-
dictor of mortality in patients with CCM.43,63,71
A previous study showed that the inclusion of the E/e’ ratio has im-
proved the risk prediction model beyond established risk parameters
in patients with CCM including functional class, LV ejection fraction,
and RV function.92 However, E/e’ ratio appears to have different effects
onmortality in the setting of CCM.71 In patients with mild or moderate
LV systolic dysfunction, an E/e’ ratio> 15 was a powerful predictor of
mortality. In contrast, in patients with severe systolic dysfunction, an
increased E/e’ ratio was inversely associated with mortality.71 Although
the underlying mechanism to explain these findings remains to be clari-
fied, it suggests that Chagas disease has some specific features com-
pared with heart failure from other aetiologies.
Increased left atrial (LA) volume has been shown to be an inde-
pendent predictor of survival in CCM, adding incremental prognostic
value to clinical factors, LV ejection fraction, and Doppler-derived
parameters of diastolic function.48 More recently, a study showed
that LA contractile function assessed by peak negative global LA
strain was an independent predictor of clinical events, defined as the
occurrence of a combined endpoint of all-cause mortality, stroke,
heart transplantation, atrial fibrillation, or admission for worsening
HF or cardiac arrhythmias.63 Although LA conductive function was
depressed in all groups of patients with the cardiac form, LA con-
tractile function was depressed only in those with heart failure.63
RV systolic involvement is a marker of Chagas disease severity
associated with functional capacity93 and survival.73 A study in 158 pa-
tients with dilated CCM found that RV function, assessed by RVmyo-
cardial performance index was a predictor of death, independent of
functional class and LV ejection fraction.73 Other subsequent studies
assessing risk stratification in Chagas disease have confirmed the fun-
damental role of RV function in predicting prognosis.58,71,92
In summary, several echocardiographic variables have been associ-
ated with increased mortality (Table 3).30,63,71,91,94–102 The prognos-
tic role of new echocardiographic techniques like speckle tracking
echocardiography and three-dimensional echocardiography is prom-
ising but its ultimate usefulness for clinical purposes remains to be
defined.
Cardiac magnetic resonancemay have a role to stratify patients at risk
of ventricular arrhythmias and progression to heart failure by detect-
ing and quantifying the extension of myocardial fibrosis.57,61,103,104
Radionuclide methodsmay improve risk stratification to define cardiac
involvement in Chagas disease in patients with devices precluding CMR
Table 4 Characteristics suggestive of Chagas disease
in patients living in non-endemic countries
Epidemiological
profile
Individuals who were born in, or have lived in
endemic areas or a child of a motder from
endemic country
Clinical features Cardiac rhythm disorders, heart failure,
thromboembolic events, chest pain without
evidence of epicardial coronary artery dis-
ease. Association with megaoesophagus or
megacolon
ECG abnormalities Sinus bradycardia, right bundle branch block
with or without left anterior fascicular block,
atrioventricular blocks, frequent premature
ventricular beats, and primary ST and T wave
abnormalities
Echocardiographic
findings
Segmental wall motion abnormalities, mainly in-
ferior and inferolateral walls, left ventricular
apical aneurysms, thrombus, and dilated car-
diomyopathy with right ventricular
dysfunction
CMR and nuclear
imaging methods
Myocardial fibrosis, regional myocardial perfu-
sion defects, and sympathetic denervation
Panel A Diagnostic flow chart and suggested periodicity of
assessment.105
ECG, electrocardiogram; CMR, cardiac magnetic resonance.
aIt is reasonable to perform an echocardiogram on every patient at
the diagnosis of Chagas disease, and it should be repeated during
follow-up if the ECG becomes abnormal. Echocardiogram should
be repeated every 3–5 years in the patients with preserved left ven-
tricular ejection fraction and more often in those who have reduced
ejection fraction at the diagnosis or when clinical status change with
worsening heart failure or embolic events.
b24h Holter monitor is specially recommended in patients with
major ECG changes, including sinus node dysfunction, atrioventricu-
lar block, or frequent premature ventricular contractions, and
should be repeated when clinical status change, or when with pre-
syncope or syncope supervenes. Exercise testing at the diagnosis
may be indicated: as a substitute for Holter when this method is not
available, to detect arrhythmia; as a pre-employment evaluation to
guide physical activities; in those candidates for cardiac transplant-
ation; it should be repeated in those patients who develop new
symptoms at the same periodicity as the Holter test.
cIt can be done to assess myocardial perfusion ormyocardial sympa-
thetic innervation, mainly for patients who complain of atypical
chest pain, so as to avoid unnecessary cardiac catheterization. It
may also be useful to further stratify the risk of LV systolic deterior-
ation and the appearance of malignant arrhythmia. No recommen-
dation can be currently be set for its periodicity.
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studies, and to identity perfusion defects and myocardial sympathetic
denervation derangements that are associated with progression of LV
dysfunction and appearance of malignant ventricular arrhythmia.62,87
The main features suggestive of Chagas disease in patients living in
non-endemic zones are shown in Table 4. These characteristics help
physicians from outside Latin America to be aware of Chagas disease.
As echocardiography is widely available with relatively low cost, it
became the imaging method of choice to evaluate patients with
Chagas disease. Advantages and disadvantages of each imaging modal-
ity in the setting of Chagas disease are shown in Table 5 (supplemen
tary data). An algorithm of diagnostic steps in Chagas disease and as-
sessment periodicity is also shown in Panel A.
Key points
• Presence and extension of LGE are predictive of severe ventricu-
lar arrhythmias, heart failure, and sudden death
• It remains to be clarified whether in the patients with the indeter-
minate form of the disease, evidence of oedema or fibrosis at
CMR can predict future progression to the cardiomyopathy
Conclusions and future research
The early mortality and substantial disability caused by CCM result in
a significant economic impact. Cardiac imaging is crucial to detect the
cardiac involvement in patients with Chagas disease, stage the dis-
ease, and stratify patient risk and address management. Since unfortu-
nately, most patients live in regions with limited access to imaging
methods and point-of-care, establishment of simplified protocols,
could improve the access of these remote populations to important
information provided by diagnostic methods that could impact in the
clinical management of the disease.
There are many fields open for further research in cardiac imaging
in Chagas disease. The role of speckle tracking echocardiography to
allow for an earlier diagnosis of cardiac involvement and improve pa-
tients’ risk stratification remains to be addressed in properly powered
outcome studies. Although three-dimensional echocardiography
should be theoretically more accurate than conventional 2D echo-
cardiography in measuring LV volumes and ejection fraction in ven-
tricles with distorted geometries like those with regional aneurysms,
whether this improved accuracy would translate into increased prog-
nostic power remains to be proved. The role of three-dimensional
echocardiography could be particularly useful to assess RV involve-
ment and its prognostic impact. The prognostic role of the presence
and extension of areas of myocardial oedema and/or fibrosis by CMR
to predict future progression to cardiomyopathy, heart failure, severe
ventricular arrhythmias, and sudden death should be addressed in
well-designed multicentre outcome studies. Finally, the role of myo-
cardial perfusion scintigraphy and assessment of myocardial sympa-
thetic innervation for an early diagnosis of cardiac involvement and
prognosis in patients with Chagas disease remains to be established.
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